Unichem Laboratories Ltd
NSE:UNICHEMLAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Unichem Laboratories Ltd
Total Equity
Unichem Laboratories Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Unichem Laboratories Ltd
NSE:UNICHEMLAB
|
Total Equity
₹24.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Total Equity
₹360.1B
|
CAGR 3-Years
20%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Total Equity
₹329.2B
|
CAGR 3-Years
15%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Total Equity
₹778.2B
|
CAGR 3-Years
14%
|
CAGR 5-Years
12%
|
CAGR 10-Years
11%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Total Equity
₹196.3B
|
CAGR 3-Years
18%
|
CAGR 5-Years
9%
|
CAGR 10-Years
7%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Total Equity
₹84.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
Unichem Laboratories Ltd
Glance View
Unichem Laboratories Ltd. is a pharmaceutical company, which engages in the manufacturing and marketing of pharmaceutical formulations. The company is headquartered in Mumbai, Maharashtra and currently employs 3,167 full-time employees. The firm manufactures and markets pharmaceutical formulations as branded generics as well as generics in various markets across the world. The company is engaged in product development, process chemistry, and manufacturing complex active pharmaceutical ingredients (APIs) as well as dosage forms. The company offers an array of medicines for therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infectives, and pain management. The firm has about six plants situated at Roha and Kolhapur, Maharashtra; Pilerne, Goa; Baddi, Himachal Pradesh; Pithampur, Madhya Pradesh and Ghaziabad, Uttar Pradesh. The company has a global presence in the United States, United Kingdom, South Africa, Brazil and China. Its subsidiaries include Niche Generics Limited, Unichem Pharmaceuticals (USA), Inc., Unichem SA (Pty) Limited and Unichem (China) Pvt. Ltd., among others.
See Also
What is Unichem Laboratories Ltd's Total Equity?
Total Equity
24.3B
INR
Based on the financial report for Dec 31, 2025, Unichem Laboratories Ltd's Total Equity amounts to 24.3B INR.
What is Unichem Laboratories Ltd's Total Equity growth rate?
Total Equity CAGR 5Y
-1%
Over the last year, the Total Equity growth was 1%. The average annual Total Equity growth rates for Unichem Laboratories Ltd have been -1% over the past three years , -1% over the past five years .
